The Shire Pharmaceuticals Company is not saying whether the company plans to keep the Burlington facility owned by the newly-acquired Dyax Corporation.
Guest Jessica Bartlett of the Boston Business Journal discusses the lingering questions about the Shire-Dyax deal.
